North Texas Eye Specialists — Mesquite, Texas

North Texas Eye Specialists is a clinical research site located in Mesquite, Texas, United States 75150.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

North Texas Eye Specialists has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Epiphora.

Sponsors: Rehan Ahmed.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Mesquite

Browse all research sites in Texas · View every site in Mesquite

• SMS Clinical Research
• Southwest Rheumatology Research
• Southern Endocrinology Associates
• Research Site
• Novartis Investigative Site
• Texas Cancer Center of Mesquite
• Pfizer Investigational Site
• Novo Nordisk Investigational Site
• Investigational Site Number 840074
• GSK Investigational Site
• Southern Endocrinology Associates PA
• Southwest Rheumatology

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for North Texas Eye Specialists?

North Texas Eye Specialists has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has North Texas Eye Specialists conducted?

North Texas Eye Specialists has 1 clinical trials on record, with 1 currently active. Their work covers Epiphora.

Is North Texas Eye Specialists accredited by Crixeo Clinical Trials?

North Texas Eye Specialists has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about North Texas Eye Specialists?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.